

COVID-19 TOWN HALL

July 8, 2020



Board of Pharmacy Update

Kam Gandhi
Executive Director | AZ Board of Pharmacy

Due to the Health Emergency, the Board will no longer take walk-ins. Board staff will still be available via phone, email and by appointment. For office directory click https://pharmacy.az.gov/node/5226. Thank you for your understanding.




State and National Updates

Kelly Fine

Executive Director | Arizona Pharmacy Association


Worldwide Cases





National Cases







TOTAL CASES

2,932,596

46,329 New Cases*


TOTAL DEATHS

130,133

322 New Deaths*


New Cases by Day

The following chart shows the number of new COVID-19 cases reported each day in the U.S. since the beginning of the outbreak. Hover over the bars to see the number of new cases by day.




US Cases by County






Rate per 100,000



Show case counts or population rates in the map below?

Cases
▼


Select a county to filter the other numbers. Deaths will not be shown for counties with fewer than three deaths.




•	Number of Cases	Number of Deaths	Number of COVID-19 Tests
	105,094	1,927	811,870
	Number of New Cases reported today*	Number of New Deaths reported today*	Number of New Tests reported today*
	3,653	117	11,418
	Rate of cases, per 100,000 population	Rate of fatalities, per 100,000 population	Total Percent Positive**
	-		Total Percent Positive** 11.3%
	population	100,000 population	
	population 1,461.9	100,000 population 26.80 New PCR Tests reported	11.3%
	population 1,461.9 Total COVID-19 PCR Tests	100,000 population 26.80 New PCR Tests reported today* 10,932	11.3% PCR Percent Positive**

Daily Confirmed New Cases





Federal guidelines advise that states wait until they experience a downward trajectory of documented cases within a 14-day period before proceeding to a phased opening. In the state-specific view of the graph, this two-week period is highlighted in orange if cases are trending upward, or green if they are trending down.



Demographics



Cases

17,891

5,779

27,943

39,029

9,570

52,576

12,072

7,561

%

46%

15%

48%


13%

49%

12%

50%

11%



COVID-19 Deaths

COVID-19 Deaths (total)

1,927



Jul 9

Jun 24

ARIZONA DEPARTMENT OF HEALTH SERVICES

Health and Wellness for All Arizonans



Mar 26


Apr 10


Apr 25


Hover over the icon to get more information on the data in this dashboard.

COVID-19 Deaths by County	COVID-19 Deaths by Date of Death	Date	Age	# Deaths	%
Data will not be shown for counties with fewer than three deaths.	40	6/17/20	20-44y 65+y	62 920	5% 75%
93 97	30	6/24/20	20-44y 65+y	72 1,044	5% 75%
134 99	Мето о образования по образования п	7/1/20	20-44y 65+y	91 1,209	6% 74%
7 933 81 <3 <3		7/8/20	20-44y 55-64y 65+y	110 269 1,411	6% 14% 73%

Jun 9








May 10

May 25

Laboratory Testing





All tests completed for COVID-19






337,760

Total % Positive COVID-19 All Tests




All tests reported yesterday in Arizona



Week of June 28th: 22%



12,111 13,084







7/8/20 11.3% 13.6

9.9%

7/1/20

New Cases State 1 Arizona 4



12%

3.2%

3.4%





2.1 tests per 1,000



Percent positive is defined as number of people with a positive test result, out of all people with COVID-19 testing completed in AZ.

Tests per 1.000 people 1



Weekly trend




THIS WFFK WFFK

Above threshold?


Hospitalizations












49%


Female

COVID-19 Hospitalized Cases by Gender

51%

Male






Inpatient Bed Usage Due to COVID-19

Number of Positive or Suspected Inpatient COVID-19 Patients

		ARIZONA DEPARTMENT OF HEALTH SERVICES
- 1		Health and Wellness for All Arizonans

Date	Total (in use %)	# COVID
6/15/20	6,231 (81%)	1,506
6/22/20	6,469 (83%)	2,136
6/29/20	6,488 (85%)	2,793
7/6/20	6,472 (82%)	3,356

*Does not include 2600 surge beds



ICU Beds in Use Due to COVID-19




Number of Intensive Care Unit (ICU) Beds in Use by Positive or Suspected COVID-19 Patients

Hover over the icon to get more information on the data in this dashboard

- 4		ь.
л		
	-	
	,,	
w	u	
٠,		•

Date	Total ICU (in use%)	# COVID
6/15/20	1,307 (80%)	502
6/22/20	1,412 (84%)	614
6/29/20	1,435 (86%)	683
7/6/20	1,481 (90%)	869

*Does not include the 600 surge beds



Ventilator Usage Due to COVID-19




Number of Ventilators in Use by Positive or Suspect COVID-19 Patients


Hover over the icon to get more information on the data in this dashboard.

- 41		
	ы	
·V	ч	,

Date	Total Ventilators (in use%)	COVID Vents.
6/15/20	707 (38%)	340
6/22/20	716 (41%)	386
6/29/20	773 (45%)	455
7/6/20	895 (51%)	544



Effective Reproduction Number: R₊



Arizona-

Tests **617,812**

101,439

Current R.

1.09

WHAT SHOULD I DO WHILE I WAIT FOR MY TEST RESULTS?









Isolate

Remain in home isolation until 10 days since your symptoms started AND 3 days after your fever is gone and your symptoms have improved.

If you have never had symptoms, you should remain in home isolation until 10 days have passed since your test was collected

> Maricopa.Gov/Home IsolationGuide

Participate

Help Public Health slow the spread of COVID-19 by completing a secure form at:

Maricopa.Gov/COVIDPositive

The information you provide will help us notify contacts of exposures so they do not pass it to others.

Communicate

Notify your friends and family members who might have been exposed (starting 48 hours before your first symptoms) that you are getting tested for COVID-19.

WHAT HAPPENS IF I TEST POSITIVE?

If you provide a phone number at the time of your test, you will be contacted by Maricopa County Department of Public Health via an automated call and text message.

This call and text will provide you with 3 things.



A reminder to complete the secure form that will help Public Health notify contacts and prevent spread to others A phone number for a hotline with medical professionals who can answer your questions



A webpage where you can verify the text, phone number, and link are from Public Health

This call and text is the first contact you will receive from Public Health.

If you are identified to be at high risk for severe disease, you will also get a phone call

f you are identified to be at high risk for severe disease, you will also get a phone cal from a Public Health investigator who will learn more about your situation, answer your questions and provide you with more information on how to take care of yourself and protect those around you.


ADHS Activates Crisis Standards of Care

STATE DISASTER MEDICAL ADVISORY COMMITTEE

- Recommended implementation of Crisis Standards of Care on 6/26
- Establishing statewide standards of care ensures that all hospitals are providing the same level of care and patients are not treated by different standards.

ADHS WILL ACTIVATE CRISIS STANDARDS OF CARE

- Activate tactics to address space, staff, and resource constraints as necessary for the hospital's current situation.
- Prepare for surge and anticipate fully staffing hospitals.
- Cease all surgeries EXCEPT non-emergent, essential surgeries and procedures that do not impair the care of other patients.
- Activate Hospital Incident Command and meet with increasing frequency.
- Establish regular communication with local health jurisdiction.



A Comprehensive and Compassionate Response

3rd Edition 2020

Crisis Standards helps by increasing flexibility to facilitate more staffing which is the main need at this time



STANDING ORDER FOR COVID-19 TESTING LOCATIONS LABORATORY TEST: SARS-CoV-2 RT-PCR

This standing order is issued by Dr. Cara Christ, MD MS (NP #1639369036), Director of the Arizona Department of Health Services. This standing order authorizes any licensed pharmacist, as per guidance by Health and Human Services, to order and administer (or oversee the administration by trained personnel) a SARS-CoV-2 RT-PCR test for any individual in accordance with the conditions of this order.

PATIENT ELIGIBILITY

The following criteria are required for a pharmacist at a testing location to administer and collect a SARS-CoV-2 RT-PCR test by this standing order:

Individual who is concerned that he or she has been exposed to and infected with COVID-19

AND

Individual who has signed a consent and voluntary isolation agreement (or parent/guardian, if patient cannot legally consent)

PLAN OF CARE

A licensed pharmacist/trained personnel operating at a pharmacy or testing location may collect a nasopharyngeal swab or other appropriate clinical specimen and order a SARS-CoV-2 RT-PCR.

- A. Preparation to collect a nasopharyngeal swab:
 - Ensure correct testing materials: (1) Sterile Dacron/nylon swab with an aluminum or plastic shaft (cotton swabs with wooden shafts are not recommended); (1) Viral transport media tube with 1-3mL of sterile viral transport medium.
 - Ensure appropriate personal protective equipment for medical provider: gloves, gowns, surgical mask (or respirator) and eye protection (goggles or face shield).
- B. Instructions to collect a nasopharyngeal swab:
 - 1. By medical provider / trained personnel:
 - Tilt patient's head back 70 degrees.
 - Insert swab into nostril parallel to the palate. Leave the swab in place for a few seconds to absorb secretions.
 - o Slowly remove swab while rotating it.
 - Place tip of swab into sterile viral transport media tube and snap/cut off the applicator stick.
 - 2. By patient: Follow manufacturer-specific instructions for specimen collection.
- C. Instructions to process clinical specimens:
 - Store specimens at 2-8°C for up to 72 hours after collection. If a delay in testing or shipping is expected, store specimens at -70°C or below.
 - Process specimens in accordance with national biological safety regulations, procedures as listed under the CDC Emergency Authorization Agreement, and the supervising Arizona healthcare facility.

NOTE: Processes to collect other appropriate clinical specimens should follow test manufacturer instructions.

NOTE: Emergency medical services should be activated if a patient appears toxic, is struggling to breathe, or moribund.

FOLLOW-UP

- 1. Test results should be reported to the patient within one week of the testing unit's receipt of the test result.
 - A positive result requires continued in-home isolation per local health department recommendations.
- 2. Results should be reported to the Arizona Department of Health Services, as required by Arizona Administrative Code, R9-6-202.

Cara Christ, MD MS, Director of Arizona pepartment of Health Services

Effective Date: 4/21/2020: Expiration Date: 12/21/2020

Standing Order Extended

Only cover PCR tests at this time. Not requirement to use this.

ARIZONA COVID-19

Hospital Resource Guide

How can hospitals request STAFF to support COVID-19 response needs?

- □ Submit a request to local public health to use <u>ESAR-VHP</u>: <u>Emergency System for Advanced Registration for Volunteer Health Professionals</u> is a registry for paid or unpaid health workers who can assist hospitals with an emergency
 - ☐ If staffing resources cannot be acquired through the normal recruitment process, contact local public health to try to fill the request locally through Medical Reserve Corps or other option (e.g. <u>Healthcare Coalition Partners</u>)
 - Connect with <u>local volunteer coordinators</u>, who will coordinate with ADHS to launch an alert through the ESAR-VHP network
 - ☐ If none of those work, local public health submits a 213-RR form in WebEOC to ADHS to try to source it or reach out for interstate or federal assistance
- Expanded credentialing and recredentialing: Arizona Licensing Boards have approved expanded options for retirees, out of state, or student healthcare professionals
- Review HR policies and implement rapid onboarding process: Identify Human Resources personnel to educate employees on leave policies and expedite hiring and orientation of new staff
- ☐ Review lodging and logistical support needs with local emergency management: Address logistical considerations to accommodate necessary staffing needs if appropriate and applicable
- □ Reimbursement for COVID-19 specific emergency medical services: Per <u>FEMA</u>

 <u>Policy FP 104-010-04</u> Public Assistance Program (Stafford Act) funding may be an eligible funding source

NOTE: Arizona Department of Health Services is working on an enhanced critical care staffing plan to support hospitals during COVID-19 surge and will provide more information regarding the centralized Surge Line staffing model to augment hospital surge plans when available.

How can hospitals increase SPACE to expand surge capacity?

- Activate surge plan to expand surge capacity, including the use of unlicensed space
 - There are no specific waivers for increasing space surge capacity plans allow for use of unlicensed space during a public health emergency
 - ☐ FAQs for hospitals during a declared public health emergency are available here
- □ Review existing waiver information
 - LTCF Waivers
 - EMS Waivers
 - CMS Waivers (Medicare)
 - Arizona State Licensing Waivers
- ☐ If necessary during an emergency declaration, individual facilities can request waivers for specific rules following the emergency waiver process for health care institutions
- □ Reimbursement for COVID-19 specific emergency medical services: Per <u>FEMA</u> <u>Policy FP 104-010-04</u> Public Assistance Program (Stafford Act) funding may be an eligible funding source

Additional Resources

- Arizona Crisis Standards of Care Plan (3rd Edition)
- Arizona Surge Line Website
- State Disaster Medical Advisory Committee (SDMAC) Recommendations
- Licensing FAOs
- EMResource Toolkit
- FEMA Public Assistance Disaster-Specific Guidance for COVID-19

Remdesivir Updates

Allocation & Distribution of Remdesivir: A Five-step Process



STEP 1

Hospitals input TeleTracking data*



STEP 2

ASPR notifies health departments about state/territory allocations



STEP 3

Health departments determine allocations for each hospital



STEP 4

AmerisourceBergen ships product to receiving hospitals; invoices for hospitals generated day of shipping**



STEP 5

Hospitals pay for remdesivir as they do for other products used for the treatment of COVID-19 patients

^{*}Data input likely to occur every other Monday, beginning Monday, July 6

^{**}Shipments likely to occur every other Monday, beginning the week of Monday, July 13

Diagnostic Tests with EUA's Approved for POC

DIAGNOSTIC TEST (MANUFACTURER)	DIAGNOSTIC METHOD	TIME FOR RESULTS	PATIENT CARE SETTING INSTRUMENT REQUIRED	SPECIMEN COLLECTED VIA		
				Nasopharyngeal	Nasal	Throat
ID NOW COVID-19 (Abbott)	Molecular	15 minutes	ID NOW Instrument	Swab	Swab	Swab
Accula SARS- Cov-2 Test (Mesa Biotech Inc.)	Molecular	30 minutes	Accula Dock or Silaris Dock	_	Swab	Swab
Xpert Xpress SARS-CoV-2 test (Cepheid)	Molecular	45 minutes	GeneXpert Dx and GeneXpert Infinity Systems	Swab	Swab	Swab
Sofia-2 SARS Antigen (Quidel)	Antigen	15 minutes	Sophia 2 Dock	Swab	Swab	_
Cue COVID-19 Test (Cue Health)	Molecular	25 minutes	Cue Health Monitoring System	_	Swab	_
BD Veritor System (BD Dickinson)	Antigen	15 minutes	The BD VeritorTM System for Rapid Detection of SARS-CoV-2	_	Swab	_

STANDALONE* HOME TEST KITS

TYPE OF TEST

EUA

ENTITY

Phosphorus COVID-19 RT-qPCR Test

ISSUED					
6/30/20	Kroger Health COVID-19 Test Home Collection Kit	Intended for use by individuals to self-collect <u>nasal swab</u> specimens at home, video-observed by a healthcare provider, when determined by a healthcare provider to be appropriate based on results of a COVID-19 questionnaire	IFU EUA Summary		
5/15/20	Everlywell COVID-19 Test Home Collection Kit	Intended for use by individuals to self-collect <u>nasal swab</u> specimens at home, when determined by a healthcare provider to be appropriate based on results of a COVID-19 questionnaire.	IFU EUA Summary		
*Testing is limite complexity tests		at are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to positive certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.	erform high		
	TESTIN	IG LIMITED TO AUTHORIZED LAB ONLY			
• KPMAS	COVID-19 Test				
• <u>Gravity I</u>	Diagnostics COVID-19 Assay				
 <u>LabCorp</u> 	LabCorp COVID-19 RT-PCR Test				
	Quest SARS-CoV-2 rRT-PCR				
_	Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2-Assay (Saliva Test)				
	Fulgent COVID-19 by RT-PCR Test				
_	P23 Labs TaqPath SARS-CoV-2 Assay				
 <u>LetsGet</u> 	LetsGetChecked Coronavirus (COVID-19) Test				

RESOURCES

Hydroxychloroquine

- A new study reported in the <u>International Journal of Infectious Diseases</u> suggests early treatment with hydroxychloroquine may be beneficial for hospitalized people infected with SARS-CoV-2.
- Researchers at the Henry Ford Health System said its study of 2,541
 hospitalized patients found that those given hydroxychloroquine were much
 less likely to die.
 - In the study, 26% of those not given hydroxychloroquine died, compared to 13% of those who got the drug.

Pharmacy Coalition Urges Federal Government To Authorize Pharmacist-provided Covid-19 Vaccines

























June 29, 2020

Robert P. Charrow General Counsel Office of the General Counsel U.S. Department of Health and Human Services 200 Independence Ave., S.W., Room 713-F Washington, D.C. 20201

Re: Authorization for Licensed Pharmacists to Order and Administer COVID-19 Vaccines under the PREP Act

Dear Mr. Charrow:

As organizations representing pharmacists and pharmacies, we are proud of the crucial efforts that our members have undertaken to help our nation respond to the COVID-19 pandemic by providing patients access to tests for the COVID-19 virus. The Department of Health and Human Services ("HHS") helped expand the availability of COVID-19 tests on April 8, 2020, when HHS issued official guidance declaring that licensed pharmacists are authorized under the Public Readiness and Emergency Preparedness ("PREP") Act to order and administer FDA-authorized

- Specifically, we ask HHS to declare under the PREP Act that licensed pharmacists are authorized to order and administer all COVID-19 vaccines that the Food and Drug Administration ("FDA") authorize or approve to prevent the COVID-19 virus.
- To avoid confusion and assure rapid patient access to COVID-19 vaccines, we ask HHS to specify that the requested PREP Act declaration preempts state and local requirements that prohibit or effectively prohibit pharmacists from ordering and administering FDA-authorized or approved COVID-19 vaccines to meet the needs of their communities.

Coronavirus Researchers Start To Enroll Subjects For Vaccine Tests

- Trials for COVID-10 vaccines need to enroll enough healthy patients in different parts of the United States and abroad with sufficient numbers exposed to the virus to allow researchers to measure their effectiveness.
- Several of the Phase III trials are expected to begin in coming weeks, including three
 30,000-person trials that are federally funded:
 - Moderna's vaccine beginning in (July)
 - University of Oxford and AstraZeneca (August)
 - Johnson & Johnson (September)
- Pfizer and BioNTech SE also intend to commence their own 30,000-person trial of their vaccine in July.

CLICK HERE

Questions?